½ÃÀ庸°í¼
»óÇ°ÄÚµå
1443877
¼¼°è ½Å¾à°³¹ß ½ÃÀå : Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Drug Discovery - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
½Å¾à°³¹ß ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 1,001¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â¿¡´Â 1,377¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß(2024-2029³â) CAGRÀº 6.59%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
COVID-19°¡ ³Î¸® ÆÛÁø °¡¿îµ¥, °¢±¹ÀÇ º¸°Ç ½Ã½ºÅÛÀº ¹ÙÀÌ·¯½º¿¡ ´ëÇ×Çϱâ À§ÇÑ ¿¬±¸ °³¹ß¿¡ ±Þ¼ÓÈ÷ ÅõÀÚÇß½À´Ï´Ù. CHEMBL, ZINC, FDA ½ÂÀÎ ¾à¹°, ÀÓ»ó½ÃÇè Áß ºÐÀÚ¿¡¼ °¡´ÉÇÑ ÈÇÕ¹°À» ½ºÅ©¸®´×Çß½À´Ï´Ù. ¼¼°è ¿¬±¸ ±×·ìÀº Áõ»óÀ» ¿ÏÈÇÏ°í ¹ÙÀÌ·¯½º º¹Á¦¸¦ ¸·´Â ´É·Â¿¡ ´ëÇØ ½Å¾à°ú ±âÁ¸ ¾à¹°À» ¸ðµÎ ½ºÅ©¸®´×ÇÏ¿© COVID-19 Ä¡·áÁ¦¸¦ È®ÀÎÇß½À´Ï´Ù. ÀÌ¿Í °°ÀÌ, ½Å¾à°³¹ß ½ÃÀåÀº COVID-19ÀÇ Ä¡·á¹ýÀ» ã¾Æ³»°íÀÚ ÇÏ´Â Ã浿¿¡ ÀÇÇØ Ç÷¯½ºÀÇ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ, À¯Çà Ä¡·á ÈÄ COVID-19 ¹× ±âŸ ½Å±Ô Áúȯ ¸ðµÎ¸¦ ´ë»óÀ¸·Î ÇÑ À¯ÀüÀÚ ¿ä¹ý ¹× ¼¼Æ÷ ¿ä¹ýÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Á¢±Ù¹ýÀÇ ÀǾàÇ° °³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç ½ÃÀå ºÐ¼®¿¡ µû¸£¸é ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ COVID-19ÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦¹° °³¹ßÀ» À§ÇÑ ¿¬±¸´Â ¾ÆÁ÷ ÁøÇà ÁßÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 5¿ù, ±¹¸³ ¾Ë·¹¸£±â °¨¿° ¿¬±¸¼Ò(NIAID)´Â ÆÒµ¥¹ÍÀÌ ¿ì·ÁµÇ´Â º´¿øü¸¦ À§ÇÑ 9°³ÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦¹° ¹ß°ß(AViDD) ¼¾Å͸¦ ¼³¸³Çϱâ À§ÇØ ¾à 5¾ï 7,700¸¸ ´Þ·¯¸¦ ¼ö¿© Çß½À´Ï´Ù. AViDD ¼¾ÅÍ´Â COVID-19 Ç×¹ÙÀÌ·¯½ºÁ¦ÀÇ Èĺ¸, ƯÈ÷ º´¿ø ¹Û¿¡¼µµ »ç¿ëÇÒ ¼ö ÀÖ´Â Ç×¹ÙÀÌ·¯½ºÁ¦³ª ¹Ì·¡ À¯Ç༺À» ÀÏÀ¸Å³ °¡´É¼ºÀÌ ³ôÀº ƯÁ¤ ¹ÙÀÌ·¯½º Æйи®¸¦ Ç¥ÀûÀ¸·Î ÇÑ Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ âÁ¶Çϱâ À§ÇØ, µ¶Ã¢ÀûÀÌ°í ÇÐÁ¦ÀûÀÎ Á¶»ç¸¦ ½Ç½ÃÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º¸Á¶±ÝÀº À¯Çà ÈÄ ½Å¾à°³¹ß ½ÃÀåÀÇ ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½Å¾à°³¹ß ½ÃÀå ¼ºÀåÀÇ ÃËÁø¿äÀÎÀ¸·Î´Â ±¤¹üÀ§ÇÑ Áúȯ(½ÉÇ÷°ü ÁúȯÀ̳ª ÁßÃß ½Å°æ°è Áúȯ µî)ÀÇ ºÎ´ã Áõ°¡, ÀÇ·áºñ Áõ°¡, ºí·Ï¹ö½ºÅÍ ÀǾàÇ°ÀÇ Æ¯Çã ¸¸·á µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.
½ÉÇ÷°ü Áúȯ, °¨¿°, ´ç´¢º´, ½ÅÀå °ü·Ã ÇÕº´ÁõÀº ¼¼°èÀûÀ¸·Î ¸Å¿ì À¯ÇàÇÏ°í ÀÖ½À´Ï´Ù. WHO°¡ 2021³â 6¿ù¿¡ ¹ßÇ¥ÇÑ ½ÉÇ÷°ü Áúȯ(CVD)¿¡ °üÇÑ ÁÖ¿ä »ç½Ç¿¡ µû¸£¸é, CVD´Â ¼¼°è »ç¸ÁÀÇ 1À§À̸ç Àü ¼¼°è »ç¸ÁÀÇ ¾à 32%¸¦ Â÷ÁöÇÕ´Ï´Ù. CVD´Â ¿©ÀüÈ÷ »ç¸Á°ú ½Åü Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀÌ¸ç ¸Å¿ì º¹ÀâÇÏ°í ºñ¿ëÀÌ ¸¹ÀÌ µé°í ºÎ´ãÀÌ Å®´Ï´Ù. ¶ÇÇÑ È¯ÀÚÀÇ °æÇè°ú ¸ñ¼Ò¸®¸¦ ´õ¿í Áß½ÃÇÏ¸é¼ ÀÓ»ó½ÃÇèÀÇ ÇÕ¸®È¿Í ºñ¿ë Àý°¨À» µµ¸ðÇÏ´Â »õ·Î¿î Àü·«ÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ¸ðµç ¿¬·ÉÃþ¿¡¼ ´Ù¾çÇÑ Áúº´ÀÇ ºÎ´ãÀÌ Áõ°¡ÇÏ°í ±× ºÎ´ãÀÌ ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀÌ ½Å¾à°³¹ß ¼ö¿ä¿Í ±× ½ÃÀåÀ» °ßÀÎÇÏ°í ÀÖ½À´Ï´Ù.
°Ô´Ù°¡ ´õ ³ªÀº ÀǾàÇ° È常¦ È®ÀÎÇϱâ À§ÇØ HTPD(High Throughput Process Development), ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º, Á¶ÇÕ ÈÇаú °°Àº ÷´Ü ±â¼úÀÇ »ç¿ëÀÌ ±ÞÁõÇÏ°í ÀÖ½À´Ï´Ù. ÀǾàÇ°Àº »õ·Î¿î ±â¼ú·Î Å©°Ô ÁøÈÇÏ¿© °øÁ¤ÀÌ ´õ¿í Á¤±³ÇÏ°í Á¤È®ÇÏ¸ç ½Ã°£ È¿À²ÀÌ ¶Ù¾î³³´Ï´Ù. Áúº´ Áø´Ü ¹× Ä¡·á ¼³°è¿¡ ÀÖ¾î¼ÀÇ ÀΰøÁö´É ½Ã½ºÅÛÀÇ Ã¤¿ëÀº È®´ëµÇ°í ÀÖ¾î ÇâÈÄ ¼ö³â°£Àº °ßÁ¶ÇÑ ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 3¿ù, AI ±â¹Ý ½Å¾à°³¹ß ±â¾÷ÀÎ Existencia´Â COVID-19 Ç×¹ÙÀÌ·¯½º ¿ä¹ýÀ» È®ÀÎÇϱâ À§ÇØ ´ÙÀ̾Ƹóµå ¶óÀÌÆ® ¼Ò½º ¹× Scripps Research¿Í °øµ¿ °è¾àÀ» ü°áÇß½À´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ ¿äÀÎÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±×·¯³ª °Å¾×ÀÇ ¼³ºñÅõÀÚ, ³·Àº ÀÌÀÍ·ü, ¾ö°ÝÇÑ ½Å¾à°³¹ß±ÔÁ¦°¡ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÆÒµ¥¹Í(¼¼°èÀû À¯Çà) µ¿¾È »ý¹°ÇÐÀû Á¦Á¦ ƯÀ¯ÀÇ ÀåÁ¡, ƯÈ÷ Ç¥Àû ƯÀ̼ºÀ¸·Î ÀÎÇØ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Ã¤¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ´Ù´Â °ÍÀº ½ÃÀå Á¶»ç¿¡ ÁÁÀº ¡ÈÄÀÔ´Ï´Ù. ±× °á°ú, ¸¹Àº ¼±µµÀûÀÎ »ý¸í °øÇРȸ»çµéÀÌ SARS-CoV-2 °Ô³ðÀ» Á¶»çÇÏ°í Ä¡·áÁ¦¸¦ ÁغñÇϱâ À§ÇÑ °æÀïÀÇ ÇÑ°¡¿îµ¥¿¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ COVID-19´Â SARS-CoV-2¿¡ ´ëÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ °³¹ß Áõ°¡·Î »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù, AbCellera»ç´Â Eli Lilly and Company(Lilly»ç)¿ÍÀÇ Á¦ÈÞ¿¡ ÀÇÇØ °³¹ßµÈ µÎ ¹ø° Ç×üÀÎ bebtelovimab(LY-CoV1404)À» Ãâ½ÃÇÏ¿© °æµµ¿¡¼ ÁߵÀÇ COVID-19ÀÇ Ä¡·áÁ¦·Î FDA¿¡¼ ±ä±Þ »ç¿ë Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù.
»ý¹°ÇÐÀû Á¦ÇüÀº ¸Å¿ì È¿°úÀûÀÌ°í °·ÂÇÑ ÀÛ¿ë, ºÎÀÛ¿ëÀÌ Àû°í, ´Ü¼øÈ÷ Áõ»óÀ» Ä¡·áÇÒ »Ó¸¸ ¾Æ´Ï¶ó Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ´Â °¡´É¼º°ú °°Àº ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.
»ý¹°ÇÐÀû Á¦ÇüÀÇ È¿´É°ú ¾ÈÀü¼ºÀº »ç¶÷µéÀÇ ±Þ¼ÓÇÑ Ã¤¿ëÀ¸·Î À̾îÁö°í ÀÖÀ¸¸ç »ý¹°ÇÐÀû Á¦Çü ºÎ¹®ÀÇ ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ »ý¹°Á¦Á¦ °³¹ßÀ» À§ÇÑ ½Å¾à°³¹ß±â¾÷°£ÀÇ Á¦ÈÞ°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù, Sanofi Innovent Biologics´Â ¾Ï Ä¡·áÁ¦ÀÇ °³¹ßÀ» °¡¼ÓÈÇÏ°í Áß±¹¿¡¼ÀÇ Á¸À縦 È®´ëÇϱâ À§ÇÑ Àü·«Àû Á¦ÈÞ¸¦ ¸Î¾ú½À´Ï´Ù. ¶ÇÇÑ 2022³â 2¿ù¿¡´Â Abzena, Alira Health, OncodesignÀÌ DRIVE »ý¹°Á¦Á¦¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ È¸»çµéÀº »ý¹° Á¦Á¦ÀÇ ½Å¾à°³¹ß °³¹ß ÇÁ·Î±×·¥¿¡¼ ½Ã³ÊÁö È¿°ú¿Í Àü¹® Áö½ÄÀ» ÆÄÆ®³Ê¿¡°Ô Á¦°øÇϱâ À§ÇØ ÄÁ¼Ò½Ã¾ö¿¡ Âü¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ »ý¹°Á¦Á¦ÀÇ °³¹ß°ú ä¿ëÀÌ Áõ°¡Çϱ⠶§¹®¿¡ ÀÌ·¯ÇÑ Á¦ÈÞ°¡ ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, ±¹Á¦ ±ÔÁ¦ ´ç±¹¿¡ ÀÇÇÑ »ý¹° Á¦Á¦ÀÇ ½ÂÀÎ Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù, FDA´Â È޹жó(¾Æ´Þ¸®¹«¸¿)ÀÇ È£È¯ ¹ÙÀÌ¿À½Ã¹Ð·¯·Î¼, ¾Ë¸®¶ó´Ù(¾Æ´Þ¸®¹«¸¿-afzb)ÀÇ »ý¹°Á¦Á¦ ½ÂÀÎ ½Åû(BLA)¿¡ ´ëÇÑ »çÀü ½ÂÀÎ º¸Ãæ(PAS)À» ½É»ç¿¡ Á¢¼öÇß½À´Ï´Ù. ÀÌ·¯ÇÑ À̴ϼÅƼºê´Â »ý¹°ÇÐÀû Á¦Á¦ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ »ý¹°ÇÐÀû Á¦Çü ºÎ¹®ÀÌ ÇöÀúÇÏ°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì´Â ÀǾàÇ°°ú »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼¼°èÀÇ ¿¬±¸°³¹ßºñ Áß Å« Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ºÀå ¿äÀÎÀ¸·Î´Â ÀǾàÇ° °³¹ß ±â¾÷¿¡ ÀÇÇÑ ÅõÀÚ Áõ°¡, ¹Ì±¹ Á¤ºÎ·ÎºÎÅÍÀÇ °Å¾×ÀÇ º¸Á¶±Ý, ´ë±â¾÷ÀÇ ÀǾàÇ° °³¹ß ±â¾÷ÀÇ °ß°íÇÑ ¹ßÆÇ, Á¤ºñµÈ Çコ Äɾî ÀÎÇÁ¶ó, ¸¸¼º Áúȯ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, ACSÀÇ "Cancer Facts & Figures 2022"¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â 2022³â ¸»±îÁö ¾à 1,918,030¸íÀÇ ½Å±Ô¾Ï ȯÀÚ¿Í 609,360¸íÀÇ ¾Ï¿¡ ÀÇÇÑ »ç¸ÁÀÚ°¡ º¸°íµÉ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â ¾Ï ¹ß»ý·üÀÌ ³ô±â ¶§¹®¿¡ ¾Ï¿¡ ´ëÇÑ ½Å¾à°³¹ßÀÌ ÃËÁøµÇ¾î ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡, ¹Ì±¹¿¡¼ÀÇ ½Å¾à°³¹ßÀÇ ±â¼úÀû Áøº¸ Áõ°¡´Â ÀÌ Áö¿ªÀÇ ½Å¾à°³¹ß ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù, CytoReasonÀº ÆÄÀÌÀú¿Í ´Ù³â°£ÀÇ ÆÄÆ®³Ê½ÊÀ» ü°áÇÏ°í, ÆÄÀÌÀúÀÇ ½Å¾à°³¹ß ÇÁ·Î±×·¥¿¡ »çÀÌÅ丮Á¸ÀÇ ÀΰøÁö´É ±â¼úÀ» »ç¿ëÇÏ°Ô µÇ¾ú½À´Ï´Ù. ½Å¾à°³¹ß¿¡ AI ±â¼úÀ» µµÀÔÇϱâ À§ÇÑ ¹Ì±¹ÀÇ ÁÖ¿ä ½ÃÀå ¼±¼öµé »çÀÌÀÇ ÀÌ·¯ÇÑ Çù¾÷Àº ÀÌ Áö¿ª¿¡¼ ¿¬±¸µÈ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½Å¾à°³¹ß ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½Å¾à°³¹ß ½ÃÀåÀº °æÀïÀÌ Ä¡¿ÇÏ°í ¼ö¸¹Àº ´ë±â¾÷ÀÌ ÁøÀÔÇÏ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼±¼ö´Â Çõ½ÅÀûÀÎ Àü·«À» µµÀÔÇÏ°í ½Å¾à°³¹ß¿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» äÅÃÇÏ¿© ÇÁ·Î¼¼½º ¼Óµµ¸¦ ³ôÀÌ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå ±â¾÷Àº Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ¸Î°í »õ·Î¿î ÀǾàÇ° ºÐÀÚ¸¦ °³¹ßÇÏ°í ÀÖ½À´Ï´Ù.
The Drug Discovery Market size is estimated at USD 100.10 billion in 2024, and is expected to reach USD 137.72 billion by 2029, growing at a CAGR of 6.59% during the forecast period (2024-2029).
Amid the COVID-19 pandemic, the health systems of various countries rapidly invested in research and development to combat the virus. Potential compounds were screened from the CHEMBL, ZINC, FDA-approved drugs, and molecules under clinical trials. Research groups worldwide have identified drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and stop viral replication. Thus, the drug discovery market was positively impacted due to the urge to find a cure for COVID-19. Furthermore, post the pandemic, there is a rise in investments in different modalities of drug development, such as gene and cell therapies for both COVID-19 diseases and other novel diseases, which is expected to impact the market's growth as per the analysis positively. Furthermore, the research for developing antiviral drugs for COVID-19 is still in progress. For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID) awarded approximately USD 577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. The AViDD centers will carry out creative, interdisciplinary research to create candidate COVID-19 antivirals, particularly those that can be used outside of a hospital setting, as well as antivirals that target particular viral families with a high potential to trigger a pandemic in the future. Such grants are expected to drive the drug discovery market's growth post-pandemic.
The propelling factors for the growth of the drug discovery market include the rising burden of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and the upcoming patent expiration of blockbuster drugs.
Cardiovascular diseases, infectious diseases, diabetes, and kidney-related complications are highly prevalent worldwide. According to key facts about cardiovascular diseases (CVDs) published by the WHO in June 2021, CVDs are the leading cause of death globally, representing around 32% of all global deaths. CVD remains the leading cause of death and disability and remains highly complicated, costly, and burdensome. Moreover, new strategies are required to streamline and reduce the costs of clinical trials while placing greater importance on the patient experience and voice. Thus, the increasing burden of a diverse range of diseases among all age groups and its burden globally drive the demand for drug discovery and its market.
Furthermore, there has been an upsurge in the usage of advanced technologies, such as high-throughput process development, bioinformatics, and combinatorial chemistry, for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and time-efficient. The adoption of artificial intelligence systems in disease diagnostics and treatment design is growing, and this is expected to witness robust growth in the coming years. For instance, in March 2020, Existencia, an AI-based drug discovery company, entered a collaborative agreement with Diamond Light Source and Scripps Research to identify COVID-19 antiviral therapies. Thus, these factors are anticipated to contribute to the market's growth over the forecast period.
However, the huge capital investment, low-profit margins, and stringent drug discovery regulations are expected to hinder the market growth.
During the pandemic, the rising adoption of biologics due to their specific advantages, especially target specificity, bodes well for the market studied. As a result, many major biotech firms are in the middle of a race to investigate the SARS-CoV-2 genome and prepare therapeutics. Furthermore, COVID-19 has significantly impacted the growth of biologics due to the rise in the development of biologics for SARS-CoV-2. For instance, in February 2022, AbCellera launched bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera's collaboration with Eli Lilly and Company (Lilly), which has received Emergency Use Authorization from the FDA for the treatment of mild to moderate COVID-19.
Biologic drugs offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to cure diseases rather than merely treat the symptoms, significantly increasing the demand for these products.
The efficacy and safety of biologics have led to their rapid adoption by people, driving the growth of the biologics segment. This has led to an increase in partnerships among drug discovery companies for the development of biologics. For instance, in August 2022, Sanofi and Innovent Biologics entered a strategic collaboration to accelerate the development of oncology medicines and expand their presence in China. In addition, in February 2022, Abzena, Alira Health, and Oncodesign launched DRIVE biologics. These companies are entering a consortium to offer their partners synergy and expertise in biologics drug discovery and development programs. Such partnerships are expected to drive the growth of this segment due to the rise in the development and adoption of biologics for various diseases over the forecast period.
Moreover, the rise in approvals for biologics from international regulatory agencies is further expected to propel the growth of this segment. For instance, in February 2022, the FDA accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab). Such initiatives are expected to drive the growth of the biologics segment.
Therefore, owing to the above-mentioned factors, the biologics segment is expected to experience tremendous growth.
North America has a significant share of the world's R&D spending on pharmaceuticals and biologics. The factors contributing to the growth of this region include a rise in investments by drug development companies, huge grants from the government of the United States, a strong foothold of major drug development companies, well-developed healthcare infrastructure, and a rise in chronic diseases, among others.
For instance, according to the ACS "Cancer Facts & Figures 2022," around 1,918,030 new cancer cases and 609,360 deaths due to cancer are estimated to be reported in the United States by the end of 2022. Such a high incidence of cancer in this region is anticipated to drive drug discovery for cancer, driving the market growth.
Furthermore, the rise in technological advancements in drug discovery in the United States is expected to drive the drug discovery market in this region. For instance, in September 2022, CytoReason entered a multi-year partnership with Pfizer to use CytoReason's artificial intelligence technology for Pfizer's drug development program. Such collaborations among key market players in the United States to implement AI technology in drug discovery are expected to drive the growth of this market studied in this region.
Therefore, owing to the above-mentioned factors, the drug discovery market is expected to increase over the forecast period.
The drug discovery market is highly competitive and consists of a number of major players. The market players are implementing innovative strategies and adopting artificial intelligence and machine learning in drug discovery to speed up the process. Furthermore, the key market players are entering into strategic partnerships to develop novel drug molecules. Some of the companies in this market include Eli Lilly and Company, Novartis AG, Bayer AG, AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Pfizer Inc., and Sanofi.